Verona Pharma plc Verona Pharma Plc : Pdmr Dealing
01 December 2017 - 12:57AM
UK Regulatory
TIDMVRP TIDMVRP
LONDON, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP)
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical
company focused on developing and commercializing innovative therapies
for respiratory diseases, announces that, on November 29, 2017, Dr.
David Ebsworth, Non-Executive Chairman of the Company, purchased 10,000
ordinary shares of 5 pence each in the Company (the "Ordinary Shares")
at a price of 106.85 pence per Ordinary Share. Following the
acquisition, Dr. Ebsworth will have an interest in the Company of
135,787 Ordinary Shares, representing 0.13% of the Company's issued
share capital.
The notification set out below is provided in accordance with the
requirements of the EU Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name David Ebsworth
2 Reason for the notification
a) Position/status Non-Executive Chairman
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Verona Pharma plc
b) LEI 213800EVI6O6J3TIAL06
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
a) Description of the financial Ordinary Shares of 5 pence each
instrument, type of instrument
Identification code GB00BYW2KH80
b) Nature of the transaction David Ebsworth purchased 10,000
Ordinary Shares
c) Price(s) and volume(s) Price(s) Volume(s)
106.85 pence per 10,000 Ordinary
Ordinary Share Shares
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 29 November 2017
f) Place of the transaction London Stock Exchange, AIM
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44 (0) 20 7710 7600
and UK Broker) SNELVeronaPharma@stifel.com
Stewart Wallace / Jonathan Senior / Ben Maddison
This announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
contained therein.
Source: Verona Pharma plc via Globenewswire
http://www.veronapharma.com/
(END) Dow Jones Newswires
November 30, 2017 08:57 ET (13:57 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Verona Pharma Plc (London Stock Exchange): 0 recent articles
More Verona Pharma News Articles